About 17 results found for searched term "Pz-1" (0.055 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M4954 | EPZ015666 | PRMTs |
| GSK3235025 | ||
| EPZ015666 is a potent, selective and orally bioavailable PRMT5 inhibitor with Ki of 5 nM, >20,000-fold selectivity over other PMTs. | ||
| M5229 | EPZ020411 | PRMTs |
| EPZ-020411 | ||
| EPZ020411 is a potent and selective inhibitor of PRMT6 with IC50 of 10 nM, has ＞10 fold selectivity for PRMT6 over PRMT1 and PRMT8. | ||
| M5289 | PZM21 | Opioid Receptor |
| PZM21 is a potent and selective μ-opioid-receptor (μOR) agonist with an EC50 of 1.8 nM. | ||
| M8621 | Pz-1 | Others |
| Pz-1 is a cell-permeable, non-cytotoxic (up to 0. | ||
| M8649 | GSK591 | PRMTs |
| GSK-591; GSK3203591; EPZ015866 | ||
| GSK591 (EPZ015866) is a potent and selective inhibitor of protein methyltransferase 5 (PRMT5) with an IC50 of 4 nM. | ||
| M8933 | EPZ011989 | Histone Methyltransferase |
| EPZ011989 is a potent, orally-available EZH2 inhibitor with Ki < 3 nM for EZH2 wt and EZH2 Y646. | ||
| M9420 | GSK3326595 | PRMTs |
| EPZ015938; GSK-3326595 | ||
| GSK3326595 is a potent, reversible and selective protein arginine methyltransferase 5 (PRMT5) inhibitor with broad antiproliferative activity for studies related to lymphoma and leukemia. | ||
| M9794 | Ebselen | Calcium Channel |
| SPI-1005; PZ-51; CCG-39161 | ||
| Ebselen (SPI-1005) is a potent voltage-dependent calcium channel (VDCC) blocker. Ebselen is an inhibitor of HIV-1 capsid CTD dimerization. Ebselen can permeate the blood-brain barrier and has anti-inflammatory, antioxidant and anticancer activity | ||
| M10637 | GSK3368715 2HCl | PRMTs |
| EPZ019997 2HCl | ||
| GSK3368715 2HCl is a novel potent, orally active, reversible type I protein arginine methyltransferases (PRMTs) inhibitor, with IC50 values of 3.1 nM, 48 nM, 1148 nM, 5.7 nM and 1.7 nM for PRMT1, PRMT3, PRMT4, PRMT6, PRMT8, respectively. | ||
| M11033 | EPZ020411 hydrochloride | PRMTs |
| EPZ020411 hydrochloride is a potent and selective PRMT6 inhibitor, IC50 10 nM, which is more than 10 times more selective than acting on PRMT1 and PRMT8. | ||
| M13846 | EPZ011989 trifluoroacetate | Histone Methyltransferase |
| EPZ-011989 trifluoroacetate | ||
| EPZ011989 trifluoroacetate is a potent, selective orally bioavailable EZH2 inhibitor with Ki < 3 nM for EZH2 wt and EZH2 Y646; 15-fold selectivity over EZH1 and >3000-fold selectivity over other HMTase. | ||
| M20752 | PZ-2891 | Others |
| PZ-2891 is a selective, orally active and brain-penetrant pantothenate kinase (PANK) modulator that acts as an orthosteric inhibitor at high concentrations and an allosteric activator at lower sub-saturating concentrations. PZ-2891 inhibits PANK with IC50 of 40.2 nM, 0.7 nM and 1.3 nM for hPANK1β, hPANK2, and hPANK3, respectively. | ||
| M21516 | PZ-128 | PAR |
| P1pal-7 | ||
| PZ-128 (P1pal-7), a cell-penetrating peptide, is a first-in-class, specific and reversible protease activating receptor 1 (PAR1) antagonist. It has anti-platelet, anti-metastasis, anti-angiogenesis and anticancer effects. | ||
| M21676 | EPZ-719 | Histone Methyltransferase |
| EPZ719 | ||
| EPZ-719 is a First-in-Class, novel and potent SET domain-containing protein 2 (SETD2) inhibitor (IC50 = 0.005 μM), with a high selectivity over other histone methyltransferases. | ||
| M22261 | EPZ031686 | Others |
| EPZ031686 | ||
| M28726 | GSK3368715 | Histone Methyltransferase |
| EPZ019997 | ||
| GSK3368715 (EPZ019997) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)). GSK3368715 (EPZ019997) produces a shift in arginine methylation states, alters exon usage, and has strong anti-cancer activity. | ||
| M56056 | EPZ011989 hydrochloride | Histone Methyltransferase |
| EPZ011989 hydrochloride is a potent and orally active Zeste Homolog 2 (EZH2) inhibitor, with a Ki value of <3 nM. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
